Pediatric Nephrology

, Volume 25, Issue 4, pp 747–752

Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients



The vast majority of kidney transplant recipients undergo triple maintenance immunosuppression that includes the use of steroids. Irrespective of their long history in organ transplantation and proven efficacy in preventing acute graft rejection, steroids exhibit an unfavourable toxicity profile, including growth retardation in children. Given these negative effects, therapeutic approaches that will substantially decrease patients’ exposure to steroids have been considered. The planned approaches included alternate day administration, rapid or late steroid withdrawal at the pre-scheduled time after transplantation and complete steroid avoidance. All three of these strategies have been tested in single- or multicentre studies and shown to have distinct clinical advantages in terms of decreasing the incidence and severity of specific adverse events. However, the safety of these protocols could not be universally proven. The Stanford study showed that a complete steroid avoidance under the “cover” of tacrolimus, mycophenolate mofetil and extended daclizumab induction is a very effective regimen for obtaining an improvement in post-transplantation growth. The recently reported international randomized TWIST trial demonstrated growth improvement as early as 6 months post-transplantation. These protocols may potentially enable paediatric renal graft recipients to safely avoid steroid exposure.


Growth Induction Renal transplant Steroid avoidance 


  1. 1.
    Kasiske BL, Chakkera HA, Louis TA, Ma J (2000) A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11:1910–1917PubMedGoogle Scholar
  2. 2.
    Pascual J, Zamora J, Galeano C, Royuela A, Quereda C (2009) Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 1:CD005632PubMedGoogle Scholar
  3. 3.
    Matas A (2009) Minimization of steroids in kidney transplantation. Transplant Int 22:38–48CrossRefGoogle Scholar
  4. 4.
    Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A (2003) Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 3:306–311CrossRefPubMedGoogle Scholar
  5. 5.
    ter Meulen CG, van Riemsdijk I, Hené RJ, Christiaans MH, Borm GF, van Gelder T, Hilbrands LB, Weimar W, Hoitsma AJ (2004) Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 4:803–810CrossRefPubMedGoogle Scholar
  6. 6.
    Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M, CARMEN Study Group (2005) Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 79:807–814CrossRefPubMedGoogle Scholar
  7. 7.
    Vítko S, Klinger M, Salmela K, Wlodarczyk Z, Tydèn G, Senatorski G, Ostrowski M, Fauchald P, Kokot F, Stefoni S, Perner F, Claesson K, Castagneto M, Heemann U, Carmellini M, Squifflet JP, Weber M, Segoloni G, Bäckman L, Sperschneider H, Krämer BK (2005) Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil - in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 80:1734–1741CrossRefPubMedGoogle Scholar
  8. 8.
    Hodson EM, Knight JF, Shell AG, Roy LP (1989) Cyclosporin A as sole immunosuppressive agent for renal transplantation in children: effect on catch-up growth. Transplant Proc 21:1687–1692PubMedGoogle Scholar
  9. 9.
    Reisman L, Lieberman KV, Burrows L, Schanzer H (1990) Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation 49:76–80CrossRefPubMedGoogle Scholar
  10. 10.
    Birkeland SA, Larsen KE, Rohr N (1998) Pediatric renal transplantation without steroids. Pediatr Transplant 12:87–92Google Scholar
  11. 11.
    Ellis D (2000) Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants. Pediatr Nephrol 14:689–694CrossRefPubMedGoogle Scholar
  12. 12.
    Höcker B, John U, Planik C, Wühl E, Weber L, Misselwitz J, Rascher W, Mehls O, Tönshoff B (2004) Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation 78:228–234CrossRefPubMedGoogle Scholar
  13. 13.
    Silverstein DM, Aviles DH, LeBlanc PM, Jung FF, Vehaskari VM (2005) Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients. Pediatr Transplant 9:589–597CrossRefPubMedGoogle Scholar
  14. 14.
    Oberholzer J, John E, Lumpaopong A, Testa G, Sankary HN, Briars L, Kraft KA, Knight PS, Verghese P, Benedetti E (2005) Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant 4:456–463CrossRefGoogle Scholar
  15. 15.
    Motoyama O, Hasegawa A, Ohara T, Satoh M, Shishido S, Honda M, Tsuzuki K, Kinukawa T, Hattori M, Ito K, Ogawa O, Yanagihara T, Saito K, Takahashi K, Ohshima S (2005) A prospective trial of steroid withdrawal after renal transplantation treated with cyclosporine and mizoribine in children: results obtained between 1990 and 2003. Pediatr Transplant 9:232–238CrossRefPubMedGoogle Scholar
  16. 16.
    Hamiwka LA, Burns A, Bell L (2006) Prednisone withdrawal in pediatric kidney transplant recipients on tacrolimus-based immunosuppression: four-year data. Pediatr Transplant 10:337–344CrossRefPubMedGoogle Scholar
  17. 17.
    Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O Jr (2001) Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 72:13–21CrossRefPubMedGoogle Scholar
  18. 18.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O Jr (2003) Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 76:1331–1339CrossRefPubMedGoogle Scholar
  19. 19.
    Li L, Chang A, Naesens M, Kambham N, Waskerwitz J, Martin J, Wong C, Alexander S, Grimm P, Conception W, Salvatierra O, Sarwal MM (2009) Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant 9:1362–1372CrossRefPubMedGoogle Scholar
  20. 20.
    Sarwal MM, Benfield M, Ettenger R, Dharnidharka V, Mathias R, McDonald R, Harmon W, Kershaw D, Vehaskari V, Kamil E, Baluarte H, Warady B, Ikle D, Bridges N, Sigdel T, Li L, Salvatierra O (2009) One year results of a prospective, randomized, multicenter trial of steroid avoidance in pediatric renal transplantation (IPTA abstract LB2). Pediatr Transplant 13(S1):63Google Scholar
  21. 21.
    Grenda R, Watson A, Trompeter R, Tönshoff B, TWIST Study Group (2009) Early steroid withdrawal in paediatric kidney recipients after two-doses of daclizumab induction, tacrolimus and MMF versus tacrolimus, MMF and steroids—TWIST Study (IPTA abstract 453). Pediatr Transplant 13(S1):154–155Google Scholar
  22. 22.
    Kumar AM, Saeed IM, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC (2008) Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol 20:32–42CrossRefPubMedGoogle Scholar
  23. 23.
    Kumar AM, Khan S, Ranganna K, Malat G, Sustendo-Reodica N, Meyers WC (2008) Long-term outcome of early steroid withdrawal after kidney transplantation in African American recipients monitored by surveillance biopsy. Transplantation 8:574–585CrossRefGoogle Scholar
  24. 24.
    Hokken-Koelega A, Stijnen T, de Jong RC, Donckerwolcke RA, Groothoff JW, Wolff ED, Blum WF, de Muinck Keizer-Schrama SM, Drop SL (1996) A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplantation. Kidney Int Suppl 53:S128–S134PubMedGoogle Scholar
  25. 25.
    Maxwell H, Reese L (1998) Randomized controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. Arch Dis Child 79:481–487CrossRefPubMedGoogle Scholar
  26. 26.
    Guest G, Berard E, Crosnier H, Chevallier T, Rappaport R, Broyer M (1998) Effects of growth hormone in short children after renal transplantation (French Society of Pediatric Nephrology). Pediatr Nephrol 12:437–446CrossRefPubMedGoogle Scholar
  27. 27.
    Fine RN, Sablein D, Cohen AH, Tejani A, Kohaut E (2002) Recombinant human growth hormone post-renal transplantion in children; a randomized controlled study of NAPRTCS. Kidney Int 62:688–696CrossRefPubMedGoogle Scholar
  28. 28.
    Tyden G, Wernenson A, Sandberg J, Berg U (2000) Development of renal cell carcinoma in living donor kidney grafts. Transplantation 70:1650–1656CrossRefPubMedGoogle Scholar
  29. 29.
    Mehls O, Wilton P, Lilien M, Berg U, Broyer M, Rizzoni G, Waldherr R, Opelz G (2002) Does growth hormone treatment affect the risk of post-transplant renal cancer. Pediatr Nephrol 17:984–989CrossRefPubMedGoogle Scholar
  30. 30.
    Fine RN, Stablein D (2005) Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry. Pediatr Nephrol 20:404–408CrossRefPubMedGoogle Scholar
  31. 31.
    Dhanidharka VR, Talley LI, Martz KL, Stablein DM, Fine RN (2008) Recombinant growth hormone use pretransplant and risk of post-transplant lymphoproliferative disease—a report of NAPRTCS. Pediatr Transplant 12:689–695CrossRefGoogle Scholar
  32. 32.
    Tönshoff B, Haffner D, Albers N, Offner G, Mehls O (1996) Predictors of the response to growth hormone in short prepubertal children post-renal transplant. German Study Group for Growth Hormone Treatment in Children Post Renal Transplantation Study Group Members. Br J Clin Pract Suppl 85:34–37PubMedGoogle Scholar

Copyright information

© IPNA 2009

Authors and Affiliations

  1. 1.Department of Nephrology, Kidney Transplantation and HypertensionChildren’s Memorial Health InstituteWarsawPoland

Personalised recommendations